| Literature DB >> 25647444 |
Aristea Kalikaki1, Alexandra Voutsina, Anastasios Koutsopoulos, Chara Papadaki, Maria Sfakianaki, Emmanouel Yachnakis, Alexandros Xyrafas, Athanasios Kotsakis, Sofia Agelaki, John Souglakos, Dimitrios Mavroudis, Vassilis Georgoulias.
Abstract
Polymorphisms in ERCC1, XPD, and XRCC1 were examined for (a) association with the clinical outcome of 107 non-small cell lung cancer patients receiving front-line platinum-based chemotherapy, and (b) correlation with the ERCC1 mRNA levels of 176 chemo-naive primary tumors. The ERCC1-C8092 allele and the number of ERCC1 polymorphic variants (C8092A and Asn118Asn) were associated with progression-free survival. In non-squamous histology, tumoral ERCC1 mRNA levels were lower in patients homozygous for ERCC1-C8092 as compared with the patients carrying the A allele (p = .024). These findings merit investigation in larger cohorts of patients treated with uniform regimens.Entities:
Keywords: ERCC1; Non-small cell lung cancer; Platinum compounds; Polymorphism; Primary tumors; mRNA levels
Mesh：
Substances：
Year: 2015 PMID： 25647444 DOI： 10.3109/07357907.2014.1001897
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176